SCHEMBL17429595

SCHEMBL17429595

O=C(O)Cc1cc(Cl)ccc1I

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.50
NFE2L2 Q16236 1/20 0.50
CXCL8 P10145 1/20 0.46
CYP2C9 P11712 1/20 0.46
CHRM1 P11229 1/20 0.46
MAPT P10636 2/20 0.44
SUCNR1 Q9BXA5 1/20 0.40
GRIK1 P39086 1/20 0.40
PTGDR2 Q9Y5Y4 2/20 0.40
PTGDR Q13258 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
AKR1B1 P15121 2/20 0.39
CASP1 P29466 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
SLC22A1 O15245 1/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
HSP90AA1 P07900 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3365496 0.85 KEAP1 (0.50) KEAP1NFE2L2CXCL8CYP2C9CHRM1
SCHEMBL16041940 0.82 KEAP1 (0.54) KEAP1NFE2L2CXCL8CYP2C9CHRM1
SCHEMBL2578143 0.80 CXCL8 (0.57) KEAP1NFE2L2CXCL8CYP2C9CHRM1
SCHEMBL29497752 0.80 CXCL8 (0.57) KEAP1NFE2L2CXCL8CYP2C9CHRM1
SCHEMBL3825211 0.79 POLQ (0.41) MAPTCASP1SMN1; SMN2MEN1SLC22A1
SCHEMBL3141863 0.78 HIF1A (0.61) KEAP1NFE2L2CXCL8CYP2C9CHRM1
SCHEMBL868684 0.78 KEAP1 (0.51) KEAP1NFE2L2CXCL8CYP2C9CHRM1
Hydrochloric Acid SCHEMBL1373062 0.78 CXCL8 (0.55) KEAP1NFE2L2CXCL8CYP2C9CHRM1
SCHEMBL1614038 0.77 KEAP1 (0.50) KEAP1NFE2L2CXCL8CYP2C9CHRM1
SCHEMBL6950315 0.77 KEAP1 (0.50) KEAP1NFE2L2CXCL8CYP2C9CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202401-B2 Process for making tetracyclic heterocycle compounds MSD R&D CN CO., LTD (CN) 2019-02-12 US disclosed
US-20180065985-A1 PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS MERCK SHARPE & DOHME CORP. (US) 2018-03-08 US disclosed
US-20180065985-A1 PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS MERCK SHARPE & DOHME CORP. (US) 2018-03-08 US disclosed
US-20170166586-A1 PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS MSD R&D (CHINA) CO., LTD (CN) 2017-06-15 US disclosed
US-20170166586-A1 PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS MSD R&D (CHINA) CO., LTD (CN) 2017-06-15 US disclosed
WO-2016004899-A1 PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2016-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202401-B2 Process for making tetracyclic heterocycle compounds CYP1B1, CYP1A2, CYP2F1 KEAP1 855/4885NFE2L2 1225/4885CXCL8 3424/4885
US-20170166586-A1 PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS CYP1A2, CYP3A5, CYP1B1 KEAP1 770/4885NFE2L2 1355/4885CXCL8 3385/4885
US-20180065985-A1 PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS CYP1B1, CYP1A2, CYP2F1 KEAP1 855/4885NFE2L2 1225/4885CXCL8 3424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.